Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugates (FABACs). Its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, specifically Non-Alcoholic Steato-hepatitis (NASH), which constitutes an unmet medical need. The Company has completed three clinical trials of aramchol. The Company focuses on providing a multi-center, double-blind, randomized Phase IIb placebo-controlled clinical trial of aramchol in NASH patients who also suffer from obesity and insulin resistance.
The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Address
AMOT HAMISHPAT BLDG. 8 SHAUL HAMELECH BLVD.
TEL AVIV-YAFO, 6473307
Israel
TEL AVIV-YAFO, 6473307
Israel
Website
http://www.galmedpharma.com/Key stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | - | -3768.32% |
| Return on average equity | - | - |
| Employees | 5 |
No comments:
Post a Comment